{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:38:56Z","timestamp":1789706336827,"version":"4.0.1"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Early-life use of acid-suppressive therapy has increased over the past 2 decades. Although these medications are widely used, recent studies showed an association between early-life use of acid-suppressive therapy and various long-term outcomes, including celiac disease.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the association between early-life use of acid-suppressive therapy and the risk of celiac disease autoimmunity using 2 observational approaches on a large population-based database.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The cohort study took place in Israel using Maccabi Healthcare Services data. The data were collected on December 8, 2023, and were initially analyzed from January to May 2024. Analysis of the data continued during the revision rounds that took place from October 2024 to February 2025. Children born between January 1, 2005, and December 31, 2020, were included, grouped based on their exposure to acid-suppressive therapy within the first 6 months after birth and subsequently followed up for outcome development until the age of 10 years or December 8, 2023. A retrospective matched cohort design (N\u2009=\u200979\u202f820) and retrospective matched test-negative case-control design (n\u2009=\u200924\u202f684), including only the population tested for celiac disease autoimmunity, were used separately and compared.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Prescription purchase of acid-suppressive therapy, either proton-pump inhibitors or histamine-2 receptor antagonists, during the first 6 months of life.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Celiac disease autoimmunity was defined as a positive anti\u2013transglutaminase 2 enzyme-linked immunosorbent assay test result according to the thresholds of the commercial kits used. Time to first positive result for celiac disease autoimmunity was defined as the outcome in the cohort design, and acid-suppressive therapy use was defined as the outcome in the test-negative design.<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort design included 79\u202f820 children (41\u202f319 boys with no acid-suppressive therapy use [51.8%]; median birth year, 2015 [IQR, 2011-2018]), of whom 19\u202f955 (25.0%) used acid-suppressive therapy. The rate of celiac disease autoimmunity was significantly higher among children using acid-suppressive therapy than among those not using acid-suppressive therapy (1.6% [310 of 19\u202f955] vs 1.0% [610 of 59\u202f865]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). The adjusted hazard ratio of acid-suppressive therapy use for development of celiac disease autoimmunity was 1.52 (95% CI, 1.33-1.74). In the test-negative case-control design, a total of 24\u202f684 children were included (62.2% girls; median birth year, 2012 [IQR, 2009-2016]), of whom 6176 (25.0%) were celiac disease autoimmunity positive. The rate of acid-suppressive therapy users among those who tested positive for celiac disease autoimmunity was not significant compared with those who tested negative (5.0% [309 of 6176] vs 4.6% [858 of 18\u202f508]; P<\/jats:italic>\u2009=\u2009.25). The adjusted odds ratio of a positive celiac disease autoimmunity test for acid-suppressive therapy use was 1.07 (95% CI, 0.94-1.23), which was nonsignificant compared with the population that tested negative.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This retrospective study included both cohort and test-negative case-control designs. In the cohort design, acid-suppressive therapy was significantly associated with celiac disease autoimmunity. In the test-negative case-control design, this association was not significant. These results suggest a residual confounding by health care utilization in cohort designs studying celiac disease and suggest a noncausal association between acid-suppressive therapy and celiac disease autoimmunity.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.3376","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:50:59Z","timestamp":1743814259000},"page":"e253376","source":"Crossref","is-referenced-by-count":2,"title":["Early-Life Exposure to Acid-Suppressive Therapy and the Development of Celiac Disease Autoimmunity"],"prefix":"10.1001","volume":"8","author":[{"given":"Tomer","family":"Achler","sequence":"first","affiliation":[{"name":"School of Medicine, Tel Aviv University Faculty of Medical and Health Sciences, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Patalon","sequence":"additional","affiliation":[{"name":"Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Gazit","sequence":"additional","affiliation":[{"name":"Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomi","family":"Cohen","sequence":"additional","affiliation":[{"name":"School of Medicine, Tel Aviv University Faculty of Medical and Health Sciences, Tel Aviv, Israel"},{"name":"Pediatric Gastroenterology Institute, Dana-Dwek Children\u2019s Hospital, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Shaoul","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology & Nutrition Institute, Ruth Children\u2019s Hospital of Haifa, Rambam Medical Center, Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ben-Tov","sequence":"additional","affiliation":[{"name":"School of Medicine, Tel Aviv University Faculty of Medical and Health Sciences, Tel Aviv, Israel"},{"name":"Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel"},{"name":"Pediatric Gastroenterology Institute, Dana-Dwek Children\u2019s Hospital, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"1","key":"zoi250168r1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/archdischild-2023-325802","article-title":"Association of early-life exposure to acid-suppressive therapy and fractures during childhood: a retrospective cohort study.","volume":"109","author":"Achler","year":"2023","journal-title":"Arch Dis Child"},{"issue":"1","key":"zoi250168r2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2625","article-title":"Early acid suppression therapy exposure and fracture in young children.","volume":"144","author":"Malchodi","year":"2019","journal-title":"Pediatrics"},{"key":"zoi250168r3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpeds.2022.10.013","article-title":"Acid suppression and antibiotics administered during infancy are associated with celiac disease.","volume":"254","author":"Boechler","year":"2023","journal-title":"J Pediatr"},{"issue":"6","key":"zoi250168r4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","article-title":"Global prevalence of celiac disease: systematic review and meta-analysis.","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10344","key":"zoi250168r5","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/S0140-6736(22)00794-2","article-title":"Coeliac disease.","volume":"399","author":"Catassi","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"zoi250168r6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.gastro.2020.06.098","article-title":"Epidemiology, presentation, and diagnosis of celiac disease.","volume":"160","author":"Lebwohl","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"zoi250168r7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097853","article-title":"Antibodies in the diagnosis of coeliac disease: a biopsy-controlled, international, multicentre study of 376 children with coeliac disease and 695 controls.","volume":"9","author":"Wolf","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"zoi250168r8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14309\/ajg.0000000000002075","article-title":"American College of Gastroenterology guidelines update: diagnosis and management of celiac disease.","volume":"118","author":"Rubio-Tapia","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"zoi250168r9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MPG.0000000000002497","article-title":"European Society Paediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2020.","volume":"70","author":"Husby","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"zoi250168r10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8227(10)70002-4","article-title":"Observational studies: going beyond the boundaries of randomized controlled trials.","volume":"88","author":"Yang","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"9596","key":"zoi250168r11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"zoi250168r12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/apt.16282","article-title":"Increased incidence of coeliac disease autoimmunity rate in Israel: a 9-year analysis of population-based data.","volume":"53","author":"Lechtman","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"zoi250168r14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"issue":"1","key":"zoi250168r15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/EDE.0000000000001116","article-title":"The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology.","volume":"31","author":"Chua","year":"2020","journal-title":"Epidemiology"},{"issue":"5","key":"zoi250168r16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.vaccine.2023.12.013","article-title":"Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: a systematic methodology review.","volume":"42","author":"M\u00e9sidor","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"zoi250168r17","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41467-022-30884-6","article-title":"Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine.","volume":"13","author":"Patalon","year":"2022","journal-title":"Nat Commun"},{"issue":"15","key":"zoi250168r18","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMe2113151","article-title":"COVID-19 vaccine effectiveness and the test-negative design.","volume":"385","author":"Dean","year":"2021","journal-title":"N Engl J Med"},{"issue":"37","key":"zoi250168r19","doi-asserted-by":"publisher","first-page":"20585","DOI":"10.2807\/1560-7917.ES2013.18.37.20585","article-title":"The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.","volume":"18","author":"De Serres","year":"2013","journal-title":"Euro Surveill"},{"issue":"2","key":"zoi250168r20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/EDE.0000000000001709","article-title":"Comparison of the test-negative design and cohort design with explicit target trial emulation for evaluating COVID-19 vaccine effectiveness.","volume":"35","author":"Li","year":"2024","journal-title":"Epidemiology"},{"key":"zoi250168r21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jpeds.2022.08.023","article-title":"Trends and correlates of early-life exposure to acid-suppressant therapy in Israel (2005-2020).","volume":"252","author":"Achler","year":"2023","journal-title":"J Pediatr"},{"issue":"3","key":"zoi250168r22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/MEG.0000000000001613","article-title":"High rates of serology testing for coeliac disease, and low rates of endoscopy in serologically positive children and adults in Israel: lessons from a large real-world database.","volume":"32","author":"Guz-Mark","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"zoi250168r23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MPG.0b013e31821a23d0","article-title":"European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease.","volume":"54","author":"Husby","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"zoi250168r24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41575-021-00511-8","article-title":"Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease.","volume":"18","author":"Pinto-Sanchez","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"zoi250168r13","unstructured":"Characterization and classification of geographical units by the socio-economic level of the population: 2015. Central Bureau of Statistics, State of Israel. August 2019. Accessed February 18, 2022. https:\/\/www.cbs.gov.il\/he\/publications\/DocLib\/2019\/1765_socio_economic_2015\/e_print.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2832209\/achler_2025_oi_250168_1743011237.57031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:51:02Z","timestamp":1743814262000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2832209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.3376","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]}}}